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A synthetic biology method based on heterologous biosynthesis coupled with genome mining
is a promising approach for increasing the opportunities to rationally access natural product
with novel structures and biological activities through total biosynthesis and combinatorial
biosynthesis. Here, we demonstrate the advantage of the synthetic biology method to explore
biological activity-related chemical space through the comprehensive heterologous bio-
synthesis of fungal decalin-containing diterpenoid pyrones (DDPs). Genome mining reveals
putative DDP biosynthetic gene clusters distributed in five fungal genera. In addition, we
design extended DDP pathways by combinatorial biosynthesis. In total, ten DDP pathways,
including five native pathways, four extended pathways and one shunt pathway, are het-
erologously reconstituted in a genetically tractable heterologous host, Aspergillus oryzae,
resulting in the production of 22 DDPs, including 15 new analogues. We also demonstrate the
advantage of expanding the diversity of DDPs to probe various bioactive molecules through a
wide range of biological evaluations.
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Natural products are historically unparalleled successfulsources for drug discovery1,2. During secondary metabo-lite biosynthesis in living organisms, natural products are
formed in vivo through multi-step enzymatic reactions3,4. In
other words, natural product structures are constructed and tai-
lored in repeated interaction with proteins in cells. This biosyn-
thetic manner provides natural product with drug-advantageous
properties such as potential protein interactivity, water solubility,
and membrane permeability5. For this reason, the natural product
chemical space is highly relevant to biological space6. Therefore,
the discovery of natural products with novel structures and bio-
logical activities is an important challenge in the pharmaceutical
field. Natural products with valuable biological activities
are recognized to contain biologically relevant privileged
structures,7,8 whose analogues and congeners serve as excellent
guides to discover not only more potent bioactive compounds but
also various additional biological activities9,10. Thus, expanding
the chemical space around biologically important natural pro-
ducts may accelerate drug discovery research11. Chemical
synthesis, including divergent and diverted total syntheses, is a
powerful strategy to produce bioactive natural product analogues
and congeners12,13. A late-stage modification strategy is also a
beneficial tool to generate natural product derivatives, such as
diversity-oriented synthesis using natural products and their
intermediate starting points14–17. However, the structural com-
plexity and limited availability of natural products remain
obstacles to synthesizing a large collection of natural products
and their structural analogues in sufficient amounts. Thus, the
development of a method that enables rapid and rational access to
the chemical space around bioactive natural products and a
reliable supply is required for drug discovery.
Fungi are among the most important microbial resources for
drug discovery because of their ability to produce structurally
diverse and biologically important natural products18. It is also
well known that fungi possess extraordinary biosynthetic gene
clusters that may encode highly diverse natural product biosyn-
thetic pathways, and biosynthetic gene information has been
accumulating at a rapidly accelerating rate in the past a decade
because of genome sequencing innovation19. However, most
biosynthetic pathways distributed in fungal genomes have not
been linked with structural information20. This implies the pre-
sence of a large number of novel natural products that may be
produced via those untapped pathways. A synthetic biology
method based on heterologous biosynthesis coupled with genome
mining is a promising approach to translate enormous amounts
of biosynthetic gene information to richly diverse natural pro-
ducts. Genome mining based on biosynthetic studies has enabled
rapid access to biosynthetic pathways not only for a target natural
product and its related analogues but also for unexplored natural
products. Heterologous biosynthesis has enabled to access com-
pounds encoded by biosynthetic pathways found by genome
mining and a number of total biosynthesis of natural products
and discovering novel natural products have been reported21–28.
In addition, combinatorial biosynthesis approach is powerful tool
to generate non-natural analogues, which may be a great
advantage to construct pharmaceutical beneficial screening
library29–32. Thus, we apply the synthetic biology approach for
rationally expanding the chemical space around a target natural
product as follows (Fig. 1). The genome mining and recon-
struction of a biosynthetic pathway for a target natural product in
a heterologous host achieves its total biosynthesis, and the bio-
synthetic information allows us to mine its related biosynthetic
pathways and access its analogues. We, then, apply pathway
extension for combinatorial biosynthesis that can produce new
natural product analogues that are not programmed in nature
and more highly modified than programmed natural products.
Fungi produce decalin-containing diterpenoid pyrones
(DDPs), a type of meroterpenoid natural products composed of a
diterpenoid-derived decalin ring system linked to pyrone bio-
synthesized via polyketide pathways3. DDPs are found only in
fungi, and over 20 DDPs have been reported to date (Supple-
mentary Fig. 1). Interestingly, even small structural differences in
each DDP show a wide range of biological activities, such as
antiproliferative activity against cancer cell lines and immuno-
suppressive activity, implying that DDPs contain a privileged
structure (Fig. 2)33–41. Thus, the chemical space of DDPs is likely
relevant to a diverse biological space and expanding this space
leads to the development of a valuable screening library for drug
discovery. In addition to promising biological activities, the
structural features of DDPs render them exciting targets for total
synthesis42–44. Recently, excellent divergent total synthesis has
been reported, which enables access to four DDPs via a common
intermediate in less than twenty chemical reaction steps45.
Nevertheless, the synthesis of diverse DDPs as well as non-natural
analogues is a rather elaborate effort; and therefore, it is difficult
to prepare a large collection of DDPs and expand their chemical
space by chemical means.
Here, we demonstrate the advantage of the synthetic biology
approach based on heterologous and combinatorial biosynthesis
coupled with genome mining for constructing a biologically
relevant DDP-focused library composed of a variety of DDPs.
Although biosynthetic studies on DDPs are limited, a putative
biosynthetic gene cluster and pathway for subglutinols (subA–F)
in an entomopathogenic fungus, Metarhizium robertsii, has been
estimated (Fig. 3a). In addition, the functions of a non-reducing
polyketide synthase (NR-PKS) SubA, geranylgeranyl diphosphate
synthase (GGPPS) SubD and prenyltransferase (PT) SubC have
been identified by a heterologous expression study46. We perform
genome mining based on this information and find putative











Biosynthetic pathway for target natural product
Related pathways
Extended pathways
Fig. 1 Strategy for expanding the chemical space of a target bioactive
natural product via a synthetic biology approach. a Genome mining
and reconstruction of the target natural product biosynthetic pathway.
b Genome mining and reconstruction of the related pathways to produce
natural analogues. c Pathway extension for combinatorial biosynthesis by
adding additional enzymes to the native pathways to produce non-natural
analogues (additionally modified analogues), Grey circles, blue circles and
green diamonds show intermediates, natural analogues and non-natural
analogues, respectively. Black, blue and green arrows show biosynthetic
pathway for target natural product, its related pathways and extended
pathways, respectively.
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Metarhizium, Colletotrichum,Macrophomina and Fusarium fungi
(Fig. 3b). According to bioinformatics analyses, we design five
native pathways from those biosynthetic gene clusters and
reconstruct them in Aspergillus oryzae NSAR122–27,47, an excel-
lent heterologous host for the production of fungal natural pro-
ducts, to give intermediates and end products encoded in all the
pathways. Subsequently, we conduct pathway extension for
combinatorial biosynthesis by adding additional modification
enzymes to the native DDP pathways, yielding unnatural DDP
analogues. Overall, we successfully produce 22 DDPs including 15
analogues that have not been reported, which include inter-
mediates, end products and additionally modified analogues.
Because they all can be easily re-supplied by cultivation of the
corresponding transformant, we are able to evaluate a variety of
biological activities of the DDP-focused library and find wide
range of potent bioactivities, such as cell cytotoxicity against
cancer cell lines through mitochondrial complex III inhibition,
antiproliferative activity against cancer stem-like cells, anti-HIV,
preventing amyloid β(Aβ) aggregation in nucleation phase,
paralysing activity against adult Drosophila and suppressing
insect innate immune signal transduction. Most these biological
activities firstly have been found in DDPs in this study.
Results
Genome mining and design of DDP biosynthetic pathways. To
find biosynthetic gene clusters that may encode DDP pathways,
we performed genome mining of the public databases and our
original gene resources by using SubA (NR-PKS) as a query. As a
result, five candidate gene clusters with subA–E orthologous genes
that may encode NR-PKS, GGPPS, PT, flavin adenine dinucleo-
tide (FAD)-dependent epoxidase (FMOep) and terpene cyclase
(TC) were found in five fungal genomes, Fusarium graminearum
PH-1 (dpfgABCDEGHIJK), Macrophomina phaseolina MS6
(dpmpABCDEGHIJ) Colletotrichum higginsianum IMI349063
(dpchABCDEFGH), Metarhizium anisopliae E6 (dpmaABCDEF),
and Arthrinium sacchari (dpasABCDEF), which we previously
isolated from a spider (Fig. 3b and Supplementary Table 1). The
dpma gene cluster, which is identical to the sub gene cluster in M.
robertsii, is widely conserved across the genus Metarhizium, and
the dpfg gene cluster is also broadly distributed in the genus
Fusarium (Supplementary Fig. 2). To design native DDP bio-
synthetic pathways distributed in the five fungal genera, the five
gene clusters were comparatively analysed based on amino acid
sequence homology and reordered them as shown in Fig. 3c
(Supplementary Tables 2 and 3). The five genes (dpxxABCDE) are
highly conserved in each cluster, suggesting that all the pathways
share the biosynthetic pathway for a common intermediate 4. The
differences in the genes at the tailoring steps in each pathway may
diversify DDP biosynthesis. The three biosynthetic gene clusters
in F. graminearum (dpfg cluster), M. phaseolina (dpmp cluster)
and C. higginsianum (dpch cluster) contain two types of short
chain dehydrogenase reductase (SDR) genes, dpxxG (SDR1) and
dpxxH (SDR2). Each of the dpxxG and dpxxH genes can be
recognized as orthologous because of their high similarity (their
encoded enzymes are approximately 60% identical each other);
that is, each set of SDRs, dpfgGH, dpmpGH and dpchGH, may
provide the same product from 4. Both the dpfg and dpmp
clusters include an orthologous methyltransferase gene, dpxxI
(MT1), which it is absent in the dpch cluster, indicating that the
dpch pathway is probably divided from the dpfg and dpmp
pathways after SDR modification steps and that a remaining
dpchF (FMO) would lead to the end product in the dpch pathway.
Both the dpmp and dpfg clusters contain a P450 gene, dpmpJ and
dpfgJ, respectively, but they show low similarity to each other
(their encoded enzymes are ~20% identical to each other), sug-
gesting that the dpfg and dpmp pathways may have branched after
the MT1 modification step. Subsequently, dpmpJ and dpfgJK
afford the final products in each pathway. However, the dpas and
dpma gene clusters possess only a modifying enzyme, FMO dpasF
and FAD-dependent BBE domain-containing oxidoreductase
(BBE) dpmaF, respectively. Therefore, both pathways are likely
branched at the initial tailoring stage, leading to the final pro-
ducts. As a result, we predicted the treelike native DDP pathways,
as depicted in Fig. 3d. Considering previously reported DDPs and
their producing fungi, the dpch and dpma pathways may produce
higginsianin A40 and subglutinol A38,46, respectively. However,
the orphan dpfg, dpmp and dpas pathways may provide new DDP
analogues.
Reconstitution of DDP pathways. We reconstituted all the
pathways by stepwise introduction of the biosynthetic genes in a
heterologous host A. oryzae NSAR1 according to the hypothetical
biosynthetic pathways (Fig. 3d and Supplementary Fig. 5).
Because it is difficult to obtain genome-sequenced strains of F.
graminearum PH-1, M. phaseolina MS6, C. higginsianum
IMI349063 and M. anisopliae E6, we used F. graminearum 50218,
M. phaseolina NBRC7317, C. higginsianum MAFF305635 and M.
anisopliae NBRC103233 instead as gene donors.
Initially, we introduced dpasACD into A. oryzae to construct
the A. oryzae transformant with dpasACD (AO-dpasACD), which,
as expected, produced prenylated (C20) α-pyrone 2 (Fig. 3a and
Supplementary Fig. 7). We subsequently introduced dpasBE into
AO-dpasACD to construct AO-dpasABCDE, which provided the
common intermediate 4 (87 mg L−1) (Supplementary Fig. 7),
demonstrating its biosynthetic machinery for the first time. We
also characterized dpfgBE, dpmpBE or dpchBE as sharing the



































Fig. 2 Examples of fungal decalin-containing diterpenoid pyrones (DDPs).
DDPs have two privileged structures, pyrone (PKS) and decalin (terpenoid),
and show a wide range of biological activities.
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Fig. 3 Genome mining and design of DDP pathways. a Biosynthetic pathway for common intermediate 4. b DDP biosynthetic gene clusters distributed in
five fungal genera. c Comparative analysis of each biosynthetic gene cluster. d Design of native pathways, extended steps and one shunt pathway
heterologously reconstituted in this study and summary of products (red numbers show compounds that have not been reported.) produced through the
DDP pathways (blue square, green square, red square and black square show intermediates, end products, additionally modified products and shunt
products, respectively).
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Next, we aimed to comprehensively reconstitute modification
steps in native DDP pathways by using the 4-producing
transformants as a platform. We reconstituted the dpas and
dpma pathways by introducing an FMO gene dpasF or a BBE
gene dpmaF into AO-dpasABCDE to give AO-dpasABCDEF and
AO-dpasABCDE-dpmaF. AO-dpasABCDE-dpmaF provided sub-
glutinols A (5, 89 mg L−1) and B (6, 6 mg L−1) as previously
suggested in the sub cluster46 (Supplementary Fig. 12). On the
other hand, AO-dpasABCDEF produced a new DDP analogue
with an enone system at the C5 unit (7, 6 mg L−1) as well as
subglutinols A (5, 62 mg L−1) and B (6, 5 mg L−1) (Supplemen-
tary Figs. 12 and 13). These results suggested that both DpasF and
DpmaF are involved in tetrahydrofuran (THF) ring formation at
the C5 unit, while DpasF possesses an additional catalytic ability
of multi-step oxidations to generate the enone at the C5 unit
in 7 (Fig. 4b).
We then aimed to reconstitute the dpch, dpmp and dpfg pathways
in A. oryzae. The introduction of dpmpG or dpmpGH into
AO-dpasABCDE afforded two transformants, AO-dpasABCDE-
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13 (new) : R = OH
14 (new) : R = H
19 (new) : R = OH17 (new) : R = OH, 12S
18 (new) : R = OH, 12R
23 (new) : R = H, 12R
24 (new) : R = H, 12R
25 (new) : R = H
9 : higginsianin B
5 : subglutinol A (12S) 10 : higginsianin A
































































































































Fig. 4 Summary of enzymatic conversions in the DDP pathways. a C-8 stereochemistry inversion steps. bModifications at the C5 unit. cModifications on
the pyrone rings. d Structures of additionally modified DDPs produced through the extended pathways. e Summary of substrate selectivities of the
modification steps in the DDP pathways.
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accumulated ketone 8 (23mg L−1), while AO-dpasABCDE-
dpmpGH gave higginsianin B (9, 28 mg L−1) (Supplementary
Fig. 17). This result showed that SDR1, DpmpG, oxidized the 8S
hydroxy group to a ketone and SDR2, DpmpH, reduced the ketone
to the 8 R hydroxy group in a similar manner to that in andrastin
biosynthesis48 (Fig. 4a). We also demonstrated that dpfgGH and
dpchGH were involved in the same inversion of the stereochemistry
at C-8 (Supplementary Fig. 17). The entire dpch pathway was
heterologously reconstituted by introducing dpchGHF into a 4-
producing transformant, and the resulting transformant, as
expected, produced higginsianin A (10, 28 mg L−1) (Fig. 4b and
Supplementary Fig. 21). We reconstituted whole dpmp and dpfg
pathways by using higginsianin B (9) producing transformants as a
platform. The introduction of dpmpI and dpfgI into the platforms
yielded AO-dpasABCDE-dpmpGHI and AO-dpasABCDE-dpfgGHI,
both of which produced a new intermediate 11 (29mg L−1 and 20
mg L−1, respectively). Moreover, dpmpIJ and dpfgIJK were
introduced to construct AO-dpasABCDE-dpmpGHIJ and AO-
dpasABCDE-dpfgGHIJK. The transformant expressing the whole
dpmp gene cluster, AO-dpasABCDE-dpmpGHIJ, afforded a new
DDP with a C-26 primary alcohol on the γ-pyrone moiety (12,
21 mg L−1) (Fig. 4c and Supplementary Fig. 25). On the other hand,
the transformant expressing the whole dpfg pathway, AO-
dpasABCDE-dpfgGHIJK, produced the new DDPs 13 (major
product, 5mg L−1) and 14 (minor product, 2 mg L−1) with a
highly oxidized γ-pyrone moiety including a methyl ester (Fig. 4c
and Supplementary Fig. 25), like colletotrichin obtained from C.
nicotianae41. The results suggested that a P450, DpmpJ, oxidized C-
26 methyl to primary alcohol, DpfgJ, catalysed a three-step
oxidation at C-27 to generate a carboxylic acid as well as C-26
hydroxylation. The results also indicated that an MT1, DpfgI, is
involved in the same methylation as DpmpI, while an MT2, DpfgK,
methylates the carboxylic acid generated by DpfgJ. We thus
completely reconstructed all the DPP native pathways distributed in
five fungi, resulting in the production of 11 DDPs, including five
new analogues. As expected, the dpma and dpch pathways encoded
the biosynthetic pathways for subglutinols (5, 6) and higginsianin A
(10), respectively, and the orphan dpas, dpmp and dpfg pathways
provided new DDP analogues.
We also investigated substrate selectivities of the modification
enzymes using A. oryzae heterologous expression system. In
summary, DpmaF and DpfgJ strictly recognized the C-8
configuration, while DpasF, DpchF, DpmpI, DpfgI and DpmpJ
showed tolerant substrate selectivity, which became an
advantage for the generating diversity in combinatorial biosynth-
esis. Through the experiments, we found and reconstituted a
shunt DDP pathway in A. oryzae, which afforded viridoxin
A hydrolysate 1533 (42 mg L−1) and a new DDP analogue 16
(6 mg L−1) (Figs. 3d, 4e, Supplementary Figs. 29, 31 and
Supplementary Note 15).
Pathway extension for combinatorial biosynthesis. The reac-
tions of each enzyme in all the pathways are summarized in
Fig. 4a–c. The enzymes that catalysed C5 unit modifications were
specifically distributed in the dpma, dpas and dpch pathways,
while the enzymes involved in the pyrone moiety modifications
were localized in the other pathways. However, no pathway that
containing both C5 unit and pyrone moiety modification enzymes
is encoded in native DDP biosynthetic gene clusters. Therefore,
we aimed to generate unnatural DDPs with further modified
structures than those of the end products in each DDP pathway
and conducted combinatorial biosynthesis by combining C5 unit-
modifying pathways with pyrone-decorating pathways (Fig. 3d).
We chose dpasF among C5 unit-modifying enzymes as an addi-
tional modification enzyme, because DpasF (FMO) enables the
generation of four types of C5 unit moieties through its multi-
functional oxidative ability, and we designed two extended
pathways by adding dpasF to the dpmp and dpfg pathways. In
addition, MT1 (dpmpI) was connected to the dpas and dpch
pathways. Thus, we designed and reconstituted the four extended
pathways in A. oryzae (Fig. 3d). One transformant (dpmp path-
way+ dpasF), as expected, produced four new analogues, 17
(5 mg L−1), 18 (3 mg L−1), 19 (16 mg L−1), and 20 (5 mg L−1),
due to the promiscuity of DpmpJ (Figs. 3d, 4d and Supplemen-
tary Fig. 35). Another transformant (dpfg pathway+ dpasF)
afforded only the new analogue 21 (6 mg L−1), the most modified
compound in this study because DpfgJ (P450) strictly recognizes
C-8 stereochemistry (Figs. 3d, 4d and Supplementary Fig. 36). In
this transformant, another expected product originating from 14
could not be observed in HPLC analysis. The third transformant
(dpch pathway+ dpmpI), as expected, produced O-methylated
higginsianin A (22, 17 mg L−1), and the fourth transformant
(dpas pathway+ dpmpI) provided 23 (23 mg L−1), 24 (7 mg L−1)
and 25 (3 mg L−1) (Figs. 3d, 4d and Supplementary Fig. 40).
As expected, all the non-natural analogues produced through
combinatorial biosynthesis contained modifications on both
the C5 unit and the pyrone moiety. Since the four re-designed
extended pathways are not found in the genome databases, of
course, every compound produced through the pathways had new
structures.
Thus, we achieved the comprehensive production of fungal
DDPs through the reconstitution of five-native pathways, one
shunt pathway and four extended pathways in A. oryzae and
produced 22 DDPs, including 15 new compounds. Among these
22 compounds, 11 compounds came from native pathways, 2
compounds were biosynthesized through shunt pathways, and 9
compounds were produced via extended pathways (Supplemen-
tary Fig. 43, Supplementary Table 19). The new compounds, 7,
11–14 and 16–25 were named as FDDP A–O, respectively. All
the compounds produced in this study were purified, and their
structures were fully determined by spectral analyses. The
absolute configuration of the common intermediate (4) was
determined by the modified Mosher’s method49 (Supplementary
Fig. 10), while those of 5, 6, 9 and 10 were identified by
comparing their optical rotation with reported values40,43. The
absolute configurations of the other DDPs were determined based
on their biosynthetic relationships. The titres of all the DDPs
based on HPLC analysis of all the transformants are summarized
in Supplementary Table 19.
Antiproliferative effects on cancer stem-like cells. Initially, we
evaluated new DDP analogues for their antiproliferative activities
across the panel of 39 human cancer cell lines, JFCR3950,51. The
assay not only showed their cytotoxic effects but also provided the
characteristic profiles similar to those of antimycin A and myx-
othiazol, known inhibitor of mitochondrial complex III (Sup-
plementary Figs. 44, 45 and Supplementary Tables 21, 22). We
then revealed that most DDPs, except for enone-containing
compounds, selectively prevented mitochondrial complex III, and
the effect was the same degree as that of antimycin A in vitro
assay (Supplementary Table 20).
We also evaluated antiproliferative activity against cancer stem
cells (CSCs), which are a small sub-population in tumour bulk
identified in most cancer cells and clinical samples52. CSCs have
been a major problem in cancer therapy because they are
responsible for recurrence, metastasis and drug resistance to
chemotherapeutic agents that affect proliferative cells53–56. Anti-
CSC activity was evaluated by the inhibition of sphere-forming
ability, a well-studied method to enrich the CSC-like population,
and selective cytotoxicity against one of the most reliable CSC
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markers, aldehyde dehydrogenase (ALDH)-positive cells55. We
selected compounds 5, 11, 12, 17, 18, 20, 22 and 23 according to
dose-dependent cytotoxicity against the bulk of MCF-7 cells for
the mammosphere formation assay (Supplementary Fig. 46a).
Low-toxicity 16 was also added as a negative control. Each
compound was tested at 5 μM, and 11, 12 and 22 clearly inhibited
sphere formation (Fig. 5a, b) more effectively than the anticancer
drugs 5-fluorouracil (5-FU) and doxorubicin. Interestingly, 12
showed the strongest effect on sphere formation, while its C-8
epimer 16 did not affect sphere formation, suggesting that the 8R
configuration significantly contributed to this activity. We next
evaluated the three DDPs that inhibited mammosphere forma-
tions against ALDH-positive cells, a functional marker for breast
CSCs. MCF-7 cells were treated with 1 μM of 11, 12 or 22, and
the ALDH-positive cell population was analysed by using a
fluorescence activated cell sorter (Supplementary Fig. 46b). The
results showed that 11, 12 and 22 reduced the population of
ALDH-positive cells (Fig. 5c). The most effective compound, 12,
was tested at lower concentrations and showed selective and
potent cytotoxicity against ALDH-positive cells (Fig. 5d). Thus,
for the first time, we successfully found DDPs with potent
antiproliferative effects on the CSC-like population in MCF-7
cells, which may lead to new anti-CSC drugs. Interestingly, subtle
structural differences in DDPs generated the difference in anti-
CSC activity.
Biological activity against Drosophila. We screened the DDPs
on the Drosophila assay system for cytotoxicity, inhibitory activity
of innate immune signalling and insecticidal activity57. The
cytotoxicity of the DDPs was evaluated using two cell lines,
embryonic macrophage-derived DL1 cells58–60 and larval blood
cell-derived l(2)mbn cells61, and their IC50 values are listed in
Supplementary Table 23. Most DDPs except for compounds with
the enone at the C5 unit (7, 19 and 25) showed potent anti-
proliferative activity, and they affected DL1 cell lines more
potently. Notably, subglutinol A (5) and 21 strongly inhibited cell
growth in the DL-1 cell line (IC50= 12 nM (5) and 15 nM (21)).
We next tested the ability of the DDPs to affect the innate
immune pathways, namely, the Toll and immune deficiency
(IMD) pathways, which are the front line of defence against
infection by microorganisms57. No compound showed a
remarkable effect on the Toll pathway, while 21 inhibited the
IMD pathway with an IC50 of 0.27 ± 0.01 µM (Fig. 6a). This result
implies that the γ-pyrone moiety that is observed in 21 might
have a role in the activity and that the THF ring at the C5 unit
enhances the effect, since 13 tend to show a moderate inhibitory
effect on the IMD pathway. Then, we evaluated the insecticidal
activity of the most potent cytotoxic 5 and IMD pathway
inhibitor 21 by using adult Drosophila (Fig. 6b). The result clearly
indicates that 5 efficiently paralysed adult Drosophila 1 h after
injection, implying that subglutinol A (5) is one of the virulence
factors of entomopathogenic Metarhizium fungi against insects.
Thus, we successfully found unique biological activity against
Drosophila in 5 and 21, which may potentially be developed as
insecticides.
Anti-HIV assay. We examined the inhibitory activities of DDPs
against various species of bacteria (both gram-negative and gram-
positive bacteria), fungi and viruses. No DDPs showed significant
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Fig. 5 DDPs show anti-CSC activity in breast cancer cell line MCF-7. a Effect of DDPs on mammosphere formation. After the cells were cultured in the
presence of 5 μM DDPs for 7 days, the number of mammospheres was microscopically counted and the percentage of mammosphere-forming cells was
determined as mammosphere-forming efficiency (MFE; %). Data represent mean ± s.d. from three independent replicate experiments. P-values were
calculated by a two-sided unpaired Student’s t-test, compared with control. b Micrographs show representative images of mammosphere formation from
three independent replicate experiments using compound 11, 12, 16, 22. The scale bar, 50mm. c Effect of DDPs (1 μM, 3 days) on ALDH-positive cells in
MCF-7 cells. Data represent mean ± s.d. from three independent replicate experiments. P-values were calculated by a two-sided unpaired Student’s t-test,
compared with control. d Dose-dependent effect of compound 12 on ALDH-positive cells in MCF-7 cells. Data represent mean ± s.d. from three
independent replicate experiments. P-values were calculated by a two-sided unpaired Student’s t-test. Source data underlying Fig. 5a, c, d are provided in a
Source Data file.
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screening of the DDPs for anti-viral agents with hepatitis B virus
(HBV), measles virus (MV), Epstein-Barr virus (EBV), herpes
simplex virus (HSV) and human immunodeficiency virus-1 (HIV-
1) indicated their selective inhibition of HIV. We further inves-
tigated the anti-HIV activity of the DDPs by the MAGI assay62
using AZT as positive control (EC50= 29.7 nM and CC50 >
10000 nM). Some of compounds, such as 5, 10, 11, 12, 14, 17, 18,
20, 23 and 24, exerted specific anti-HIV activity (EC50 < 200 nM)
without affecting other viruses (Supplementary Table 24). Among
them, 20 showed the strongest anti-HIV activity without apparent
cytotoxicity (EC50= 8.5 nM and CC50 > 10,000 nM). Other com-
pounds also showed moderate to substantial activity but the
effective concentrations were high; therefore, their toxicity made it
difficult to clearly distinguish their anti-HIV effect.
Screening of amyloid Aβ 42 aggregation inhibitors. The
aggregation of the 42-mer-amyloid β (Aβ42) is involved in the
pathogenesis of Alzheimer’s disease (AD)63. A nucleation-
dependent polymerization model that is composed of nuclea-
tion and elongation phases is generally accepted as the aggrega-
tion mechanism of Aβ4264. In the nucleation phase, the monomer
of Aβ42 gradually forms low-molecular-weight oligomers (called
nuclei), which cause synaptotoxicity and memory loss65.
We evaluated the ability of DDPs to inhibit Aβ42 aggregation
by using the Th-T (thioflavin-T) assay, which is a conventional
and useful method for quantifying Aβ aggregates (Supplementary
Fig. 47). Consideration of the preliminary results and SARs, we
picked up 12, 13, 14, 20, and 21, and tested them again (Fig. 7a).
The fluorescence of Aβ42 and the Th-T complex began to
increase after 4 h of incubation, and only 13 and 21 delayed the
nucleation phase of Aβ42 until 6 and 13 h, respectively. In
contrast, the congeners of 13 and 21 regarding the primary
alcohol or methyl ester group, such as 12, 14 and 20 showed no
delay even though 12, 14 and 20 partly suppressed the elongation
of Aβ42. In TEM analysis, the formation of typical amyloid fibrils
of Aβ42 was strongly prevented only by 13 and 21, leading to the
fragmentation of fibrils (Fig. 7b).
To further analyse the inhibitory mechanism, we subjected a
mixture of Aβ42 and 21 after 1 h of incubation at room
temperature to liquid chromatography/quadrupole time-of-flight
mass spectrometry (LC/Q Tof-MS). The possible peaks of Aβ42–
21 adducts were detected, and then the mass envelopes at +7, +6,
+5, and +4 charge distribution corresponded to the Michael
adduct based on the loss of 32 Da (Supplementary Figs. 48b–d,
49). However, no such adduct was found in the presence of 20 as
a negative control (Supplementary Fig. 48a). To identify the
specific amino acids involved in the interaction of 21 with the Aβ
monomer, we performed LC–MS/MS analysis with collision-
induced dissociation (CID) using E22P, M35ox-Aβ9-35 as a toxic
conformer surrogate66,67. Based on a large number of fragmented
b ions and y ions, Lys16 in Aβ42 (DAEFRHDSGYEVHHQKLVF-
FAEDVGSNKGAIIGLMVGGVVIA) seemed to be one of the
target amino acid residues of 21 (Supplementary Fig. 50).
To investigate the reaction mechanism between the highly
oxidized γ-pyrone observed in 13 and 21, and the lysine residue
in Aβ42 with a decrease of 32 Da, we carried out the following
experiment. Benzyl-protected lysine 28 was reacted with 13 and
21 as well as the structurally related 14 and 20 in THF at room
temperature (Supplementary Note 30), and each reaction was
monitored by HPLC analysis at 1 h and 10 h after mixing
(Supplementary Fig. 51a). In the reaction of 13, two new peaks
gradually appeared at 1 h later, and 13 completely converted to
the new peaks 26 and 27 (Supplementary Fig. 51b) in 10 h. LCMS
analysis showed the same molecular ion peak of 26 and 27 at m/z
863 [M+Na]+, which suggested that 13 connected to 28 with a
decreasing of 32 Da in the same situation described above. The
reaction of 21 proceeded in the same manner as that of 13,
whereas 14 and 20 did not afford any adducts under the same
reaction conditions (Supplementary Fig. 51), suggesting that the
γ-pyrone structure, including a hydroxyl group and carboxylic
methyl ester, was necessary for the reaction. After scaling up the
reaction, we isolated 26 and 27, which are in the C-21 epimer
relationship, and determined their structures (Fig. 7c, Supple-
mentary Note 31). From their structures, we proposed the
following reaction mechanism: 13 took the ortho ester form,
which increased electrophilicity at C-24, and the amine in lysine
performed a nucleophilic attack at C-24 with elimination of the
methoxy group followed by electron transfer to form 26 and 27

























































Fig. 6 Biological activity against Drosophila. a Inhibitory effect of compound 21 on the IMD pathway Drosophila l(2)mbn cells were stimulated with heat-
killed E. coli and the activity of the Attacin promoter, a read-out of the activation of the IMD pathway, was monitored by a luciferase assay. Data are
means ± SEM of triplicate wells from a single experiment and are representative of two independent experiments. b Toxic effect of compound 5 on
Drosophila adult. Adult flies (c.a. 1 mg each) were injected with the indicated compounds (3.5 ng each), and the flies that did not show movement or only
faint shaking of their legs were counted as unmoving flies. Data are the means ± SEM of triplicate samples from a single experiment and are representative
of two independent experiments. Source data underlying Fig. 6a, b are provided in a Source Data file.
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did not react with the primary thiol in the cysteine derivative, the
hydroxyl group in the serine derivative or the guanidine group in
the arginine derivative (Supplementary Fig. 53 and Supplemen-
tary Note 32). Thus, we successfully discovered that DDPs
markedly inhibited Aβ aggregation in the nucleation phase via a
lysine-selective binding motif.
Discussion
Herein, we report the advantage of the synthetic biology approach
based on heterologous biosynthesis coupled with genome mining
for rationally expanding the chemical space of biologically active
natural products. In this study, we focused on fungal DDPs as a
natural product family including a privileged structure and aimed
to produce a diverse set of DDPs. Genome mining revealed
putative gene clusters for DDPs distributed in five fungal genera
and bioinformatics analyses were performed to draw the five
treelike DDP biosynthetic pathways. Stepwise reconstruction of
all the pathways in A. oryzae allowed us to make transformants
corresponding to all the intermediates and end products in the
pathways, resulting in the isolation of all the DDPs produced in
the native DDP pathways. From their structures, we determined
the function of all the modification enzymes in the pathways.
Subsequently, we designed four extended pathways by using the
five native pathways as tool for combinatorial biosynthesis. This
combinatorial biosynthesis enabled us to access non-natural
analogues that equipped further modifications than those of
compounds produced via native pathways. Finally, we achieved
heterologous biosynthesis of 22 DDPs, including 15 new analo-
gues, which were included intermediates, end products, shunt
products and additionally modified analogues in A. oryzae.
We then screened the DDP-focused library with various bio-
logical activity assays. DDPs produced in this study shared same
skeleton and showed similar antiproliferative activities against
cancer cells and inhibition of mitochondrial complex III each
other. However, interestingly, small structure differences in each
DDP gave unique functions of markedly reducing CSC-like
populations in MCF-7 bulk cells (11, 12 and 22), potent inhibi-
tory activity of an insect innate immune system, the IMD path-
way (21), potent paralysing activity against adult Drosophila (5),
selectively inhibited HIV proliferation (20), and Aβ aggregation
in the nucleation phase through trapping lysine residue on highly
modified γ-pyrone motif (13 and 21). Notably, compounds
produced via extended pathways indeed showed unique biological
activities. Thus, this study showcases the capability of combina-
torial synthetic biology in acceleration of drug discovery.
In the post-genomic era, a synthetic biology approach is
undoubtedly one of the most powerful methods to achieve not
only the generation of natural products from gene resources but
also the rational expansion of bioactive natural product chemical
space. The gene resources available in the method are rapidly
increasing; therefore, the method would infinitely expand the
chemical diversity of natural products and their analogues. In
addition, the method solves the supply issues and permits natural
products to be subjected to enough biological evaluations. When
the method becomes advanced and widely used, natural products
will be easier available for drug discovery and definitely increase
the opportunity to develop natural products as drug seeds68.
Methods
General methods. Polymerase chain reaction (PCR) was performed using a
TaKaRa PCR Thermal Cycler Dice® Gradient (Takara Bio) and Thermal Cycler
LifeECO (Nippon Genetics). Oligonucleotide primers for PCR were purchased
from Hokkaido System Science Co., Ltd. (Hokkaido, Japan) and listed in Supple-
mentary Table 4. Analytical and preparative TLC was performed on silica gel 60
F254 (Merck) and RP-18 F254S (Merck). Column chromatography and flash chro-
matography were carried out on silica gel 60 N (100–210 µm, Kanto Chemical) and























































































Fig. 7 Inhibitory activity of Aβ aggregation. a Selected results of the Th-T assay (n= 3). b TEM analysis of typical amyloid fibrils formed by Aβ42. Scale
bar= 100 nm. Representative micrographs are selected from at least six micrographs taken in one grid. c Hypothetical reaction mechanism of 13 and
lysine derivative 28 (13 was reacted with 28 (5.0 eq) in THF at r.t. for 10 h to give adducts 26 and 27). Source data underlying Fig. 7a, b are provided in a
Source Data file.
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recorded on a Burker AVANCE III spectrometer. Chemical shifts for 1H and 13C
NMR are given in parts per million (δ) relative to tetramethylsilane (δH 0.00) and
residual solvent signals (δC 77.0) for CDCl3 as internal standard. Reverse phase
HPLC analysis was performed on HITACHI LaChrom Elite series equipped with
L-2130 pump, L-2200 autosampler, L-2455 Diode Array Detector, and D-2000
system manager. LC-MS analysis was performed on HITACHI Chromaster series
equipped with 5110 pump, 5430 Diode Array Detector, 5610 MS Detector, MSD
system manager. High-resolution mass spectra were measured on a Thermo
Fischer Scientific Exactive Mass spectrometer. UV spectra were recorded on a
JASCO-V-730 spectrophotometer. IR spectra were recorded on JASCO-FT/IR-
4200 spectrometer. Optical rotations were recorded on JASCO-P-1030.
Genome mining and bio-informatics analyses of DDP pathways. Draft genome
sequence of A. sacchari Kumo-3 was obtained in previous study (Supplementary
Data 1)69. Draft genome sequences of F. graminearum PH-1, M. phaseolina MS6,
C. higginsianum IMI349063 and M. anisopliae E6 were obtained from National
Center for Biotechnology Information (NCBI). Genome mining was performed by
Protein BLAST search against A. sacchari Kumo-3 genome sequence and the NCBI
non-redundant database and 2ndFind program (http://biosyn.nih.go.jp/2ndfind/).
The results of bioinformatics analyses are shown in Supplementary Tables 1–3.
Fugal strains used as genomic DNA donor. Arthrinium sacchari (strain Kumo-3)
was isolated from a spider previously69. Genomic DNA of Fusarium graminearum
50218 was obtained from the Medical Mycology Research Center, Chiba University
(Chiba, Japan).Macrophomina phaseolina NBRC 7317 andMetarhizium anisopliae
NBRC 103233 were obtained from the Biological Resource Center, National
Institute of Technology and Evaluation (Chiba, Japan). Colletotrichum higginsia-
num MAFF 305635 was obtained from the Genetic Resource Center, National
Agriculture and Food Research Organization (Ibaraki, Japan).
Heterologous host. Escherichia coli DH5a (Competent quick, TOYOBO) was used
for cloning experiments. Aspergillus oryzae NSAR147, a quadruple auxotrophic
mutant (niaD−, sC−, ΔargB, adeA−) was used as the host for fungal expression.
Preparation of fungal genomic DNA. A. sacchari Kumo-3, M. phaseolina NBRC
7317, M. anisopliae NBRC 103233, and C. higginsianum MAFF 305635 were
cultivated on Potato dextrose agar (PDA) (2.4% Potato dextrose broth (Difco),
1.5% agar). The spores and mycelium from the plate were inoculated into 60 mL of
Potato dextrose medium (2.4% Potato dextrose broth). After several days culti-
vation at 30 °C (reciprocal shaking), the mycelia of each strain were collected by
filtration, washed with water, and frozen at −80 °C. The frozen mycelium was
ground to fine powder, suspended in TE buffer (pH 8.0), and equal volume of lytic
buffer (2% SDS, 0.1 M NaCl, 10 mM EDTA, 50 mM Tris-HCl) was added. After
incubation at room temperature for 5 min, the supernatant was extracted with
phenol: chloroform: isoamyl alcohol (25:24:1) solution (pH 7.9). After ethanol
precipitation, the isolated DNA was dissolved in TE buffer (pH 8.0) and stored at
−20 °C before use.
General methods for DNA engineering experiments. PCR was performed with
PrimeSTAR® Max DNA Polymerase (Takara Bio) unless otherwise noted. PCR
products and linearized plasmids were purified with QIAEX® II Gel Extraction Kit
(QIAGEN). DNA cloning experiments were performed using E. coli DH5α
(Competent Quick, TOYOBO) following standard techniques and recombinant
plasmids were extracted with GenEluteTM Plasmid Miniprep Kit (Sigma-Aldrich)
from E. coli cells.
Construction of fungal expression plasmids. The genes in dpfg, dpmp, dpch,
dpas, and dpma clusters were amplified by PCR from genomic DNA of F. gra-
minearum 50218, M. phaseolina NBRC 7317, C. higginsianum MAFF 305635, A.
sacchari Kumo-3, and M. anisopliae NBRC 103233 as templates by using gene
specific primers listed in Supplementary Table 4, respectively. The full-length genes
in each cluster were purified and inserted into restriction site (Asp718 or NotI) of
the pUARA2, pUADEA2, pUSCA2, or pUPTRA2 (Supplementary Fig. 3 and
Supplementary Note 1) to yield fungal expression plasmid. For construction of one
of two genes containing plasmids, each gene was ligated with Asp718 or/and NotI-
digested pUARA2, pUADEA2, pUSCA2, or pUPTRA2 vectors using In-Fusion®
HD Cloning Kit (Takara Bio) (Supplementary Fig. 4a). For construction of three or
four genes containing plasmids, two-gene containing DNA fragments were
amplified by PCR from the corresponding plasmids with two genes and ligated
with the linearized vector fragment(s) as described above (Supplementary Fig. 4b).
All the overexpression plasmid vectors made in this study are listed Supplementary
Table 5.
Transformation of A. oryzae. Transformation of A. oryzae was performed using
the protoplast-polyethylene glycol (PEG) method as follows: A. oryzae host strains
were cultivated on agar plate (PDA supplemented with 0.05% L-arginine and
0.05% adenine for NSAR1, CD agar supplemented with appropriate nutrients and
chemicals (Supplementary Table 6) for transformants). The spores and mycelia of
the host strain were inoculated into 60 mL of Czapek-Dox -Casamino acids
medium (3.5% Czapek-Dox broth (Difco), 0.5% Casamino acids vitamin assay
(Difco, when ptrA was used as a selectable marker) or Casamino acid (Difco, when
ptrA was not used as a selectable marker), 0.01% adenine (for adenine auxotrophic
strains)). After 20 hour cultivation at 30 °C (reciprocal shaking), mycelium was
collected by filtration and washed with water. The mycelium was incubated with
10 mL protoplasting buffer (5 mgmL−1 Yatalase (Takara Bio), 1 mgmL−1 Cellu-
lase Onozuka R-10 (SERVA Electrophoresis GmbH), 0.8 M NaCl, 10 mM phos-
phate buffer (pH 6.0)). After 3-h incubation at 30 °C, undigested mycelia was
removed by filtration with Miracloth (Merck), and the protoplasts were collected
by centrifugation at 1300 × g for 5 min. The protoplasts were washed with 0.8 M
NaCl, resuspended in solution I (0.8 M NaCl, 10 mM CaCl2, 10 mM Tris-HCl (pH
8.0)) to obtain 2.0 × 108 cells mL−1. 0.2 Volumes of solution II (40% PEG4000, 50
mM CaCl2, 50 mM Tris-HCl (pH 8.0)) was added with gentle mixing, and then
200 µL of this protoplast suspension was combined with 10–20 µg of plasmid DNA
(<20 µL). After 40 min incubation on ice, 1 mL of solution II was added to the
aliquot with gentle mixing. After another 15 min of incubation at room tempera-
ture, 20 mL of solution I was added to the mixture and the protoplasts were
collected by centrifugation at 2000 rpm for 5 min. The protoplasts were resus-
pended in 600 µL of solution I, and the suspension was combined with molten soft-
top agar (3.5% Czapek-Dox broth, 0.8 M NaCl, 0.6% agar) supplemented with
appropriate nutrients (Supplementary Table 6). Subsequently, the protoplasts were
plated on CD agar plates (3.5% Czapek-Dox broth, 0.8 M NaCl, 1.5% agarose) with
appropriate nutrients (Supplementary Table 6). After 3–7 days incubation at 30 °C,
the resultant cells (transformats) were transferred and subcultured on CD agar
plates with appropriate nutrients (Supplementary Table 6).
Reconstitution of the DDP pathways. The DDP biosynthetic genes were
stepwisely introduced in A. oryzae NSAR1 using expression plasmids containing
the aforementioned genes to construct all the transformants expressed the native
DDP pathways (Supplementary Figs. 5, 6, 11, 16, 20, 24, 28 and Supplementary
Notes 2, 7, 9, 11, 13), shunt pathway (Supplementary Fig. 30 and Supplementary
Notes 15, 16, 17) and extended pathways (Supplementary Figs. 34, 39 and Sup-
plementary Notes 19, 21)
Gene integration analysis of each A. oryzae transformant. We obtained about
four to ten transformants per one-transformation experiments. Thus, we checked
gene insertion of all the transformant by PCR. Target gene integration into the A.
oryzae transformants were confirmed by PCR with the genomic DNA template and
primers in Supplementary Table 4. Genomic DNA of the transformant was
extracted as follows; small pieces of mycelium of the A. oryzae strain were collected
from an agar plate after several days growth at 30 °C and incubated at 95 °C in TE
(pH 8.0) buffer for 10 min. The genomic DNA solution was diluted with water to
prepare the PCR template at appropriate concentration.
Cultivation and metabolite analysis of A. oryzae transformants. All the
transformant that pass the gene integration check were cultivated and analysed their
metabolite profiles by reverse phase HPLC and LC-MS analyses. Each transformant
was inoculated into 60mL of CPS medium (3.5% Czapek-Dox broth, 0.3% casein
peptone (Nacalai Tesque), 0.3% meat peptone (Nacalai Tesque), 0.3% soy peptone,
2% soluble starch (Nacalai Tesque), 1% maltose monohydrate (Nacalai Tesque),
0.01 % adenine (for adenine auxotrophic strains)) or 1/2 CPS medium (1.75%
Czapek-Dox broth, 0.15% casein peptone (Nacalai Tesque), 0.15% meat peptone
(Nacalai Tesque), 0.15% soy peptone, 1% soluble starch (Nacalai Tesque), 0.5%
maltose monohydrate (Nacalai Tesque), 0.01 % adenine (for adenine auxotrophic
strains). About 1 week (6–10 days) after cultivation at 30 °C, 150 rpm, the culture
media and mycelium were separated by filtration. The culture media (3 mL) was
extracted with EtOAc (2mL), and the organic layer was concentrated in vacuo. The
residue was then dissolved in 150 µL of MeOH to prepare sample for reverse phase
HPLC and LC-MS analysis. The freeze-dried mycelium (20mg) was extracted with
MeOH (1mL), and the extract was concentrated in vacuo. The residue was then
dissolved in 100 µL of MeOH to prepare sample for HPLC and LC-MS analysis. For
the HPLC and LC-MS analysis, 10 µL of the samples were used. The HPLC analysis
was performed on COSMOSIL 5C18 Packed Column (4.6mm I.D. × 150mm,
Nacalai Tesque) with acetonitrile and water containing 0.01% trifluoroacetic acid
(0–1.5 min: 20:80, 1.5–11.5 min: a linear gradient from 20:80 to 100:0, 11.5–20min:
100:0) at a flow rate of 1.0 mLmin−1. The LC-MS analysis was performed on
COSMOSIL 5C18 Packed Column (4.6 mm I.D. × 150mm, Nacalai Tesque) with
acetonitrile containing 0.1% formic acid and water containing 0.1% formic acid
(0–2 min: 20:80, 2–12min: a linear gradient from 20:80 to 100:0, 12–20 min: 100:0)
at a flow rate of 1.0 mLmin−1 using positive mode electro spray ionization.
Isolation and structure determination of each compound. To isolate DDPs
produced by the transformants, we picked up the transformants that produced
target DDPs the most and performed scaling up cultivation of the transformant.
Each A. oryzae transformant was cultivated in 1/2 CPS medium (1.75% Czapek-
Dox broth, 0.15% casein peptone (Nacalai Tesque), 0.15% meat peptone (Nacalai
Tesque), 0.15% soy peptone, 1% soluble starch (Nacalai Tesque), 0.5% maltose
monohydrate (Nacalai Tesque), 0.01% adenine (for adenine auxotrophic strains)
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15664-4
10 NATURE COMMUNICATIONS |         (2020) 11:1830 | https://doi.org/10.1038/s41467-020-15664-4 | www.nature.com/naturecommunications
for 1 week at 30 °C, and the culture media and mycelium were separated by
filtration. The culture media was extracted with EtOAc two times, and the organic
layer were combined and concentrated in vacuo to give crude extract. The freeze-
dried mycelium was extracted with EtOAc (20% MeOH), and the extract was
concentrated in vacuo. The mycelia extract was then dissolved in MeOH (0.1%
water), washed with hexane three times, concentrated in vacuo to give crude
extract. Each of the crude extract of culture and mycelium was fractionated by silica
gel column chromatography, and subjected to further purification by flash chro-
matography and preparative TLC (SiO2 or ODS). All the DDP structures were fully
determined by spectral analyses (Supplementary Figs. 8–10, 14, 15, 18, 19, 22, 23,
26, 27, 32, 33, 37, 38, 41, 42, 52, 54–77, Supplementary Tables 7–18, 25 and
Supplementary Notes 3–6, 8, 10, 12, 14, 18, 20, 22, 31).
Evaluation of biological activities of DDP-focused library. Purified DDPs was
dissolved in DMSO (Specially Prepared Reagent, Nuclease and Protease tested,
NACALAI, 09659-14) to prepare 5 mM solutions. The Each DDP solution (5 mM)
was used for antiproliferative effects on cancer cell lines (Supplementary Notes 23,
24, 25, 26), biological activity against Drosophila (Supplementary Note 27), anti-
HIV assay (Supplementary Note 28) and screening of amyloid Ab42 aggregation
inhibitors (Supplementary Notes 29).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data supporting the findings of this work are available within the paper and
its Supplementary Information files. A reporting summary for this Article is available as
a Supplementary Information file. The data sets generated and analyzed during this study
are available from the corresponding author upon request. The sequences data of dpasA-
F and Dpas A-F are provided as a Supplementary Data 1. The source data underlying
Figs. 5a, c, d, 6a, b, 7a, b, Supplementary Figs. 44, 46a, 47, and Supplementary Tables 20,
23, and 24 are provided as a Source Data file.
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